NEW YORK–(BUSINESS WIRE) – Scott + Scott Attorneys at Law LLP (“Scott + Scott”), an international shareholder and consumer rights law firm, is investigating whether Ardelyx Inc. (“Ardelyx” or the “Company”) (NASDAQ: ARDX) and certain its officers and directors violate federal securities laws. If you have bought or otherwise owned Ardelyx securities and suffered a loss, please contact Jonathan Zimmerman at (888) 398-9312 for more information.
Ardelyx is focused on the discovery, development and commercialization of innovative drugs for patients with kidney and heart disease.
On July 19, 2021, the US Food and Drug Administration (FDA) reported deficiencies in Ardelyx’s new drug application of Tenapanor, a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease during dialysis. In the letter, the FDA noted that the size of the treatment effect and its clinical relevance are a key issue.
As a result of this news, Ardelyx stock slumped, falling from $ 7.70 per share on July 19, 2021 to $ 2.01 per share on July 20, 2021, a decrease of nearly 74%.
What you can do
If you have purchased or otherwise own Ardelyx securities and would like to discuss this investigation, please contact Attorney Jonathan Zimmerman at (888) 398-9312 or email@example.com or visit the Ardelyx investigation page on our website at https://dev.scott-scott.com/investigation/ardelyx-inc/.
About Scott + Scott Lawyers LLP
Scott + Scott has extensive experience pursuing major securities, antitrust, and retirement measures in the United States. The firm represents pension funds, foundations, individuals and other companies worldwide with offices in New York, London, Amsterdam, Connecticut, Virginia, California and Ohio.